NASDAQ$OPK
OPKO Health Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
OPKO Health's financial performance declined due to decreased revenues and increased operating losses, but advancements were made in the product pipeline and approvals were received in China.
OPKO Health reported a decrease in consolidated total revenues to $181.9 million, compared to $185.4 million for the same period in 2022. The operating loss increased to $69.1 million, compared to $55.3 million in the prior year. Net loss was $65.5 million, or $0.09 per share, compared to a net loss of $85.2 million, or $0.11 per share, for the 2022 quarter.
- Pharmaceutical revenue increased to $43.0 million, driven by international operations and RAYALDEE sales.
- Diagnostics revenue decreased to $124.2 million due to lower clinical test reimbursement and COVID-19 testing volume.
- Operating loss increased to $69.1 million, impacted by non-recurring expenses and revenue adjustments in the diagnostics segment.
- ModeX advanced its antiviral and immune-oncology product pipeline.
Headline financials
Revenue & EPS history
OPKO Health · Revenue · Quarterly
$182M
Revenue by segment
OPKO Health · $398M total across 2 segments · Q4 2021
- Services$363M—91.1%
- Products$35.3M—8.9%
Forward guidance
OPKO's senior management will provide a business update, discuss fourth quarter financial results, provide financial guidance and answer questions during a conference call and audio webcast today beginning at 4:30 p.m. Eastern time.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
-0.7%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-0.2%
Avg return
30 days after
44%
27 / 61 earnings
Positive
+26.8%
Q1 2018
Best reaction
-17.7%
Q3 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.8% | -8.3% | +19.2% | |
| Q4 2025 | +2.5% | +0.0% | -6.7% | |
| Q3 2025 | -2.9% | -4.3% | -2.9% | |
| Q1 2025 | -2.2% | -7.2% | -1.4% | |
| Q4 2024 | +6.7% | +19.0% | +4.3% | |
| Q3 2024 | +3.4% | +9.5% | +8.2% | |
| Q2 2024 | +6.7% | +11.9% | +16.4% | |
| Q1 2024 | -5.3% | -3.0% | +1.5% | |
| Q4 2023 | -1.1% | -1.0% | +20.0% | |
| Q3 2023 | -0.7% | -6.7% | +18.5% | |
| Q2 2023 | +13.1% | +6.8% | +2.8% | |
| Q1 2023 | +15.0% | +26.5% | -1.4% | |
| Q4 2022 | +0.0% | +7.5% | +22.6% | |
| Q3 2022 | -14.8% | -9.3% | -25.8% | |
| Q2 2022 | -6.6% | +2.9% | -12.7% | |
| Q1 2022 | +11.8% | +15.6% | +8.4% | |
| Q4 2021 | +7.4% | +3.7% | +17.8% | |
| Q3 2021 | +5.9% | +16.2% | +15.4% | |
| Q2 2021 | -11.6% | -7.2% | -0.8% | |
| Q1 2021 | -3.7% | -4.2% | -10.5% | |
| Q4 2020 | -13.6% | -18.0% | -12.9% | |
| Q3 2020 | -12.0% | -11.0% | +3.3% | |
| Q2 2020 | -11.1% | -7.4% | -42.3% | |
| Q1 2020 | -15.2% | +3.9% | +2.2% | |
| Q4 2019 | +3.6% | +12.2% | +0.7% | |
| Q3 2019 | -2.0% | -2.6% | +5.3% | |
| Q2 2019 | -2.1% | -6.2% | -4.6% | |
| Q1 2019 | -16.1% | -14.9% | -22.1% | |
| Q4 2018 | -9.9% | -5.7% | -7.8% | |
| Q3 2018 | +6.7% | -7.4% | -6.0% | |
| Q2 2018 | -0.4% | -1.6% | +1.5% | |
| Q1 2018 | +26.8% | +37.8% | +23.5% | |
| Q4 2017 | -0.6% | +0.9% | -6.5% | |
| Q3 2017 | -17.7% | -20.1% | -20.2% | |
| Q2 2017 | +1.7% | -1.3% | -1.6% | |
| Q1 2017 | -3.4% | -0.8% | -13.7% | |
| Q4 2016 | -11.5% | -9.3% | -4.6% | |
| Q3 2016 | -6.6% | -3.4% | +11.8% | |
| Q2 2016 | +0.3% | -0.5% | -5.1% | |
| Q1 2016 | +6.7% | — | — | |
| Q4 2015 | +0.4% | — | — | |
| Q3 2015 | +7.6% | — | — | |
| Q2 2015 | -13.7% | — | — | |
| Q1 2015 | +4.8% | — | — | |
| Q4 2014 | -2.7% | — | — | |
| Q3 2014 | +2.5% | — | — | |
| Q2 2014 | -4.0% | — | — | |
| Q1 2014 | +8.4% | — | — | |
| Q4 2013 | -0.6% | — | — | |
| Q3 2013 | -1.4% | — | — | |
| Q2 2013 | +3.7% | — | — | |
| Q1 2013 | +3.4% | — | — | |
| Q4 2011 | -4.0% | — | — | |
| Q1 2011 | +1.3% | — | — | |
| Q1 2012 | +2.7% | — | — | |
| Q4 2009 | -2.6% | — | — | |
| Q3 2011 | -2.3% | — | — | |
| Q2 2011 | -3.3% | — | — | |
| Q4 2010 | -3.3% | — | — | |
| Q3 2010 | +0.7% | — | — | |
| Q1 2010 | +9.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro